BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16568496)

  • 21. The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity.
    Park MY; Kim CH; Sohn HJ; Oh ST; Kim SG; Kim TG
    Vaccine; 2007 Oct; 25(42):7322-30. PubMed ID: 17889413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
    Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.
    Cayeux S; Bukarica B; Buschow C; Charo J; Bunse M; Dörken B; Blankenstein T
    Gene Ther; 2007 Oct; 14(20):1481-91. PubMed ID: 17700709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes.
    Hao S; Bai O; Yuan J; Qureshi M; Xiang J
    Cell Mol Immunol; 2006 Jun; 3(3):205-11. PubMed ID: 16893501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
    Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
    Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4 T cell help is required for primary CD8 T cell responses to vesicular antigen delivered to dendritic cells in vivo.
    Serre K; Giraudo L; Siret C; Leserman L; Machy P
    Eur J Immunol; 2006 Jun; 36(6):1386-97. PubMed ID: 16673447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs.
    Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T
    Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apolipoprotein B binding domains: evidence that they are cell-penetrating peptides that efficiently deliver antigenic peptide for cross-presentation of cytotoxic T cells.
    Sakamoto N; Rosenberg AS
    J Immunol; 2011 Apr; 186(8):5004-11. PubMed ID: 21402897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2.
    Mochimaru H; Usui T; Yaguchi T; Nagahama Y; Hasegawa G; Usui Y; Shimmura S; Tsubota K; Amano S; Kawakami Y; Ishida S
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):2172-7. PubMed ID: 18263815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting dendritic cells with antigen via dendritic cell-associated promoters.
    Moulin V; Morgan ME; Eleveld-Trancikova D; Haanen JB; Wielders E; Looman MW; Janssen RA; Figdor CG; Jansen BJ; Adema GJ
    Cancer Gene Ther; 2012 May; 19(5):303-11. PubMed ID: 22361816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells.
    Robson NC; Donachie AM; Mowat AM
    Eur J Immunol; 2008 May; 38(5):1238-46. PubMed ID: 18398931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The induction of cytotoxic T cells and tumor regression by soluble antigen formulation.
    Hariharan K; Braslawsky G; Black A; Raychaudhuri S; Hanna N
    Cancer Res; 1995 Aug; 55(16):3486-9. PubMed ID: 7627951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cytotoxic T lymphocyte response against a protein antigen does not decrease the antibody response to that antigen although antigen-pulsed B cells can be targets.
    Wang W; Golding B
    Immunol Lett; 2005 Sep; 100(2):195-201. PubMed ID: 15916814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
    Donda A; Cesson V; Mach JP; Corradin G; Primus FJ; Robert B
    Cancer Immun; 2003 Aug; 3():11. PubMed ID: 12916958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination.
    Isaji K; Kawase A; Matono M; Guan X; Nishikawa M; Takakura Y
    J Control Release; 2009 May; 135(3):227-33. PubMed ID: 19331843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models.
    Park JS; Sohn HJ; Park GS; Chung YJ; Kim TG
    Cancer Sci; 2011 Aug; 102(8):1448-54. PubMed ID: 21545375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
    Kim JH; Kang TH; Noh KH; Bae HC; Kim SH; Yoo YD; Seong SY; Kim TW
    Immunol Lett; 2009 Jan; 122(1):58-67. PubMed ID: 19135479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
    Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
    J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.